Tadalafil: A new role in Raynaud's phenomenon?
Publication Type:Journal Article
Source:International Journal of Clinical Rheumatology, Volume 6, Number 2, p.115-117 (2011)
Keywords:angiotensin 2 receptor antagonist, bleomycin, bosentan, calcium channel blocking agent, continuous infusion, digital ulcer, dipeptidyl carboxypeptidase inhibitor, drug dosage form comparison, drug efficacy, drug half life, drug mechanism, drug safety, drug tolerability, erectile dysfunction, human, iloprost, ischemia, outcome assessment, patient compliance, phosphodiesterase inhibitor, phosphodiesterase V, placebo, priority journal, prostacyclin, prostacyclin derivative, pulmonary hypertension, quality of life, Raynaud phenomenon, review, scleroderma, sildenafil, skin ulcer, systemic sclerosis, tadalafil, ulcer, vasoconstriction, vasodilator agent
cited By (since 1996)0
Cite this Research Publication
P. Da Shenoy and Agarwal, Vb, “Tadalafil: A new role in Raynaud's phenomenon?”, International Journal of Clinical Rheumatology, vol. 6, pp. 115-117, 2011.
Related Research Publications
- Healing hypertension: A focus on alternative systems of medicine
- Anti-platelet agents in pediatric cardiac practice
- Janus kinase inhibitors: Jackpot or potluck?
- Incretin analogue, liraglutide a newer treatment approach for type-2 diabetes mellitus
- Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening